Literature DB >> 3165612

Spinocerebellar ataxia: variable age of onset and linkage to human leukocyte antigen in a large kindred.

H Y Zoghbi1, M S Pollack, L A Lyons, R E Ferrell, S P Daiger, A L Beaudet.   

Abstract

We studied a seven-generation kindred with autosomal dominant spinocerebellar ataxia (SCA) to assess linkage relationships to multiple human leukocyte antigen (HLA) loci on the short arm of chromosome 6. Age at onset, clinical features, and course of the disease are described. Although the mean age of onset was 34 years in this family, in 6 of 41 affected individuals onset was below 15 years of age and was accompanied by the unique clinical features of mental retardation and rapid progression of disease. Linkage studies were performed on 93 individuals, and the results show strong evidence for linkage of the SCA locus to the HLA loci. A maximum logarithm of the odds score of 5.83 was found at a recombination fraction of 0.12. This is the first documentation of childhood onset in the HLA-linked form of SCA.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3165612     DOI: 10.1002/ana.410230609

Source DB:  PubMed          Journal:  Ann Neurol        ISSN: 0364-5134            Impact factor:   10.422


  31 in total

1.  Clinical and genetic study of a family with spinocerebellar ataxia type 1 (SCA1) and beta-thalassemia.

Authors:  V Pietrini; M Godani; S Calzetti; A Negrotti; B Castellotti; M C Riggio; C Toffoli
Journal:  Ital J Neurol Sci       Date:  1998-12

Review 2.  Genomic imprinting: review and relevance to human diseases.

Authors:  J G Hall
Journal:  Am J Hum Genet       Date:  1990-05       Impact factor: 11.025

3.  Genetic fitness and selection intensity in a population affected with high-incidence spinocerebellar ataxia type 1.

Authors:  Fedor A Platonov; Kathrin Tyryshkin; Dmitriy G Tikhonov; Tatyana S Neustroyeva; Tatyana M Sivtseva; Natalya V Yakovleva; Valerian P Nikolaev; Oksana G Sidorova; Sardana K Kononova; Lev G Goldfarb; Neil M Renwick
Journal:  Neurogenetics       Date:  2016-04-22       Impact factor: 2.660

4.  Cerebellar contribution to the cognitive alterations in SCA1: evidence from mouse models.

Authors:  Melissa Asher; Juao-Guilherme Rosa; Orion Rainwater; Lisa Duvick; Michael Bennyworth; Ruo-Yah Lai; Sheng-Han Kuo; Marija Cvetanovic
Journal:  Hum Mol Genet       Date:  2020-01-01       Impact factor: 6.150

5.  Coexistence of type I familial amyloid polyneuropathy and spinocerebellar ataxia type 1. Clinical and genetic studies of a Japanese family.

Authors:  S Ikeda; N Yanagisawa; N Hanyu; K Furihata; T Kobayashi
Journal:  J Neurol Neurosurg Psychiatry       Date:  1996-05       Impact factor: 10.154

6.  Molecular and clinical correlations in spinocerebellar ataxia type I: evidence for familial effects on the age at onset.

Authors:  L P Ranum; M Y Chung; S Banfi; A Bryer; L J Schut; R Ramesar; L A Duvick; A McCall; S H Subramony; L Goldfarb
Journal:  Am J Hum Genet       Date:  1994-08       Impact factor: 11.025

7.  RNAi or overexpression: alternative therapies for Spinocerebellar Ataxia Type 1.

Authors:  Megan S Keiser; James C Geoghegan; Ryan L Boudreau; Kim A Lennox; Beverly L Davidson
Journal:  Neurobiol Dis       Date:  2013-04-10       Impact factor: 5.996

8.  The gene for autosomal dominant spinocerebellar ataxia (SCA1) maps centromeric to D6S89 and shows no recombination, in nine large kindreds, with a dinucleotide repeat at the AM10 locus.

Authors:  T J Kwiatkowski; H T Orr; S Banfi; A E McCall; C Jodice; F Persichetti; A Novelletto; F LeBorgne-DeMarquoy; L A Duvick; M Frontali
Journal:  Am J Hum Genet       Date:  1993-08       Impact factor: 11.025

9.  Tight linkage of the gene for spinocerebellar ataxia to D6S89 on the short arm of chromosome 6 in a kindred for which close linkage to both HLA and F13A1 is excluded.

Authors:  B J Keats; M S Pollack; A McCall; M A Wilensky; L J Ward; M Lu; H Y Zoghbi
Journal:  Am J Hum Genet       Date:  1991-11       Impact factor: 11.025

Review 10.  Neurogenetic diseases: molecular diagnosis and therapeutic approaches.

Authors:  U Muller; M B Graeber
Journal:  J Mol Med (Berl)       Date:  1996-02       Impact factor: 4.599

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.